AZD 6793
Alternative Names: AZD-6793Latest Information Update: 18 Jul 2024
At a glance
- Originator AstraZeneca
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
Most Recent Events
- 10 Jul 2024 AstraZeneca plans a phase I trial (In volunteers, Monotherapy, Combination therapy) in Germany (PO, Tablet), in July 2024 (NCT06494644, D7860C00004, EUCT2023-509002-30-00)
- 15 May 2024 Phase-I clinical trials in Inflammation (In volunteers) in USA (PO) (NCT06368440)
- 16 Apr 2024 AstraZeneca plans I pharmacokinetics trial in healthy adult volunteers in US in May 2024 (PO) (NCT06368440)